More cannabis reform is coming to Capitol Hill, and that’s good news for several stocks
Many investors wait to enter the market because of uncertainty and volatility or, alternatively, because the market is too expensive. Savers’ excuses for not taking the plunge into investment are continuous, and no context is conducive to doing so. However, when faced with the question of when to invest, the end of the year may be the answer. Now that 2022 is winding down, investments in cannabis stocks seem to make a lot of sense, especially since there may be some big surprises in the industry during 2023. Some stocks are positioned to close the year on a high note.
Green Thumb Industries is one of them. This company is the only pure-play multi-state operator (MSO) whose profitability is quite relevant based on its net income. According to its third-quarter report, the company reported $261 million in revenue, up 11.8% year over year and 2.7% sequentially. While its fundamentals are quite solid, the stock is down nearly 40% this year, leaving it in a buying position for investors who want a stable portfolio with great potential.
Innovative Industrial Properties is also in a bearish position at the moment as it is down 57% year-to-date. It is important to note that this real estate investment trust (REIT) trades for just over 23 times its earnings. The firm also just raised its quarterly dividend by 2.9% to $1.80 per share. It’s a smart bet for investors looking for stocks with solid financials.
And then there’s Jazz Pharmaceuticals, a company that focuses on neuroscience and oncology therapies. It is considered an ancillary cannabis stock as its antispasmodic and anticonvulsant therapies are based on marijuana compounds. Epidiolex and Sativex are two internationally recognized drugs that have improved the lives of many people suffering from these conditions.